Detailansicht

Wissensnetz

Person

Astrid Pechmann (1985-)

Name	Astrid Pechmann
Zeit	1985- (Lebensdaten)
Ort	Saarbrücken (Geburtsort) Deutschland
Geschlecht	weiblich
Akademischer Grad bzw. Titel	Dr. (an der Medizinischen Fakultät der Universität Freiburg im Breisgau) (2011)
Datensatztyp	Person
GND-Nummer	1018203060
Datensatz-ID	1018203060
Beteiligt an alle anzeigen Arzneimittellehre für Pflegeberufe Arzneimittellehre für Pflegeberufe Diagnostik und Therapie der Spinalen Muskelatrophie Efficacy and safety of gene therapy with onasemnogene abeparvovec in children with spinal muscular atrophy in the D-A-CH-region: a population-based observational study Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study Postnatal management of preterm infants with spinal muscular atrophy: experience from German newborn screening Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5‐year update of the NURTURE study De-duplicating patient records from three independent data sources reveals the incidence of rare neuromuscular disorders in Germany Evaluating case management for caregivers of children with spinal muscular atrophy type I and II—an exploratory, controlled, mixed-methods trial High-sensitive cardiac troponin I (hs-cTnI) concentrations in newborns diagnosed with spinal muscular atrophy Improvements in walking distance during nusinersen treatment – a prospective 3-year SMArtCARE registry study Newbornscreening SMA – from pilot project to nationwide screening in Germany Newbornscreening SMA – From Pilot Project to Nationwide Screening in Germany Risdiplam in types 2 and 3 spinal muscular atrophy: a randomised, placebo‐controlled, dose‐finding trial followed by 24 months of treatment Whole-Genome sequencing identified new structural variations in the DMD gene that cause duchenne muscular dystrophy in two girls Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study Deep dynamic modeling with just two time points: Can we still allow for individual trajectories? Cathepsin D as biomarker in CSF of nusinersen‐treated patients with spinal muscular atrophy Deep dynamic modeling with just two time points: can we still allow for individual trajectories? Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study Costs of Illness of Spinal Muscular Atrophy: A Systematic Review Costs of illness of spinal muscular atrophy: a systematic review Post‐dural puncture headache - a single‐centre analysis in paediatric patients with and without SMA Experiences of caregivers of children with spinal muscular atrophy participating in the expanded access program for nusinersen: a longitudinal qualitative study Advances in treatment of spinal muscular atrophy – new phenotypes, new challenges, new implications for care Arzneimittellehre für Pflegeberufe Coagulation disorders in Duchenne muscular dystrophy? Results of a registry-based online survey Congenital myasthenic syndrome with mild intellectual disability caused by a recurrent SLC25A1 variant Experiences of caregivers of children with spinal muscular atrophy participating in the expanded access program for nusinersen: a longitudinal qualitative study Handlungsempfehlungen zur Gentherapie der spinalen Muskelatrophie mit Onasemnogene Abeparvovec – AVXS-101 : : Konsensuspapier der deutschen Vertretung der Gesellschaft für Neuropädiatrie (GNP) und der deutschen Behandlungszentren unter Mitwirkung des Medizinisch-Wissenschaftlichen Beirates der Deutschen Gesellschaft für Muskelkranke (DGM) e. V. = Recommendations for gene therapy of spinal muscular atrophy with onasemnogene abeparvovec—AVXS-101 :<br>Consensus paper of the German representatives of the Society for Pediatric Neurology (GNP) and the German treatment centers with collaboration of the medical scientific advisory board of the German Society for Muscular Diseases (DGM) SMArtCARE - A platform to collect real-life outcome data of patients with spinal muscular atrophy Arzneimittellehre für Pflegeberufe De-duplicating patient records from three independent data sources reveals the incidence of rare neuromuscular disorders in Germany Increased von Willebrand factor parameters in children with febrile seizures Evaluation of children with SMA type 1 under treatment with nusinersen within the expanded access program in Germany Einfluss von Stromflussrichtung und Pulswellenkonfiguration auf motorisch evozierte Potentiale

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Astrid Pechmann (1985-)

Arzneimittellehre für Pflegeberufe

Arzneimittellehre für Pflegeberufe

Diagnostik und Therapie der Spinalen Muskelatrophie

Efficacy and safety of gene therapy with onasemnogene abeparvovec in children with spinal muscular atrophy in the D-A-CH-region: a population-based observational study

Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study

Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study

Postnatal management of preterm infants with spinal muscular atrophy: experience from German newborn screening

Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5‐year update of the NURTURE study

De-duplicating patient records from three independent data sources reveals the incidence of rare neuromuscular disorders in Germany

Evaluating case management for caregivers of children with spinal muscular atrophy type I and II—an exploratory, controlled, mixed-methods trial

High-sensitive cardiac troponin I (hs-cTnI) concentrations in newborns diagnosed with spinal muscular atrophy

Improvements in walking distance during nusinersen treatment – a prospective 3-year SMArtCARE registry study

Newbornscreening SMA – from pilot project to nationwide screening in Germany

Newbornscreening SMA – From Pilot Project to Nationwide Screening in Germany

Risdiplam in types 2 and 3 spinal muscular atrophy: a randomised, placebo‐controlled, dose‐finding trial followed by 24 months of treatment

Whole-Genome sequencing identified new structural variations in the DMD gene that cause duchenne muscular dystrophy in two girls

Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study

Deep dynamic modeling with just two time points: Can we still allow for individual trajectories?

Cathepsin D as biomarker in CSF of nusinersen‐treated patients with spinal muscular atrophy

Deep dynamic modeling with just two time points: can we still allow for individual trajectories?

Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study

Costs of Illness of Spinal Muscular Atrophy: A Systematic Review

Costs of illness of spinal muscular atrophy: a systematic review

Post‐dural puncture headache - a single‐centre analysis in paediatric patients with and without SMA

Experiences of caregivers of children with spinal muscular atrophy participating in the expanded access program for nusinersen: a longitudinal qualitative study

Advances in treatment of spinal muscular atrophy – new phenotypes, new challenges, new implications for care

Arzneimittellehre für Pflegeberufe

Coagulation disorders in Duchenne muscular dystrophy? Results of a registry-based online survey

Congenital myasthenic syndrome with mild intellectual disability caused by a recurrent SLC25A1 variant

Experiences of caregivers of children with spinal muscular atrophy participating in the expanded access program for nusinersen: a longitudinal qualitative study

SMArtCARE - A platform to collect real-life outcome data of patients with spinal muscular atrophy

Arzneimittellehre für Pflegeberufe

De-duplicating patient records from three independent data sources reveals the incidence of rare neuromuscular disorders in Germany

Increased von Willebrand factor parameters in children with febrile seizures

Evaluation of children with SMA type 1 under treatment with nusinersen within the expanded access program in Germany

Einfluss von Stromflussrichtung und Pulswellenkonfiguration auf motorisch evozierte Potentiale